We advised the underwriters on the IPO and Nasdaq listing

Davis Polk advised the representatives of the several underwriters in connection with the $151.3 million initial public offering of 7,567,000 shares of common stock of Akoya Biosciences, Inc. Akoya Biosciences’ common stock is listed on the Nasdaq Global Select Market under the symbol “AKYA”.

Akoya Biosciences offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression, treatment response, and that empower clinicians to improve patient outcomes. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. With these platforms, Akoya’s customers are performing spatial phenotyping to further advance their understanding and treatment of diseases such as cancer, neurological and autoimmune disorders, and many other therapeutic areas.

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar, counsel Jennifer Ying Lan and associate Jeannette Safi. Counsel Kiara L. Rankin provided tax advice. Partner David R. Bauer and associate Marisa Elena Bannon provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post